Latest From Exelixis Inc.
Ipsen CSO says CHMP recommendation for TKI Cabometyx should give it first mover advantage globally in liver cancer.
Portola touts exec's commercial management experience with Genentech success stories Avastin and Tarceva.
Study of PD-L1/TKI combo succeeded in an all comers population across risk groups, which could be differentiating, for a while.
Latest set of oncology clinical practice guidelines issued in September highlight Cabometyx as preferred treatment option.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Exelixis Inc.
- Senior Management
Michael M Morrissey, PhD, Pres. & CEO
Christopher J Senner, EVP, CFO
Peter Lamb, PhD, EVP, Scientific Strategy & CSO
Gisela M Schwab, MD, Pres., Prod. Dev. & CMO
- Contact Info
Phone: (650) 837-7000
210 East Grand Ave.
P.O. Box 511 S. San Francisco, CA 94083-0511
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.